Quanterix To Present At 5th Annual One Mind Summit
Lexington, Mass. – Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced that the Company’s CEO and Executive Chairman, Kevin Hrusovsky, will be presenting at the 5th Annual One Mind Summit, which takes place May 24-25, 2016, in Crystal City, VA.
The goal of the summit is to address the implementation of science-informed screening tools for mild traumatic brain injury (mTBI) and co-morbid conditions in acute care settings throughout the U.S. Hrusovsky is one of five prominent thought leaders who will address the industry’s progress toward building a commercial fluid-biomarker platform for TBI.
Session IV – Plans and Progress Toward Better Diagnostic and Prognostic Assessments for TBI and CoMorbid Conditions – Wednesday, May 25, 2016; 2:15 p.m. – 3:30 p.m.
The goal of this session is to discuss the progress toward developing objective diagnostic and prognostic tools for TBI, including blood-based and neuroimaging biomarkers, and eye-tracking devices, and to identify strategies for accelerating their validation and implementation. Mr. Kevin Hrusovsky, Executive Chairman and CEO, Quanterix Corp.
• Dr. Ramon Diaz-Arrastia, Professor of Neurology and Director of Clinical Research, Center for Neuroscience and Regenerative Medicine, Uniformed Services University of the Health Sciences (USUHS)
• Dr. Jamshid Ghajar, Director of the Stanford Concussion and Brain Performance Center, Stanford University School of Medicine, Brain Trauma Foundation, SyncThink
• Dr. Pratik Mukherjee, Professor, Department of Radiology and Biomedical Imaging, Bioengineering; Attending Neuroradiologist, University of California, San Francisco (UCSF) School of Medicine
• Dr. Diane Stephenson, Executive Director, Critical Path Institute (C-Path)
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, visit: www.quanterix.com and follow @QuanterixSimoa on Twitter. Investors can access a webcast of Kevin Hrusovsky’s recent JPMorgan presentation at: http://info.quanterix.com/watch-quanterix-jp-morgan-healthcare-presentation.
Share this page